Ensaculin Explained

Ensaculin (KA-672) is a drug from the coumarin family, which has been researched as a potential treatment for dementia. It acts on a number of receptor systems, being both a weak NMDA antagonist and a 5HT_1A agonist.^{[1] [2]} Animal studies have shown promising nootropic effects,^{[3] [4]} although efficacy in humans has yet to be proven. It was well tolerated in human trials, with the main side effect being orthostatic hypotension (low blood pressure).^[5]

See also

• Enciprazine
• Mafoprazine
• BMY-14802
• Azaperone
• Fluanisone

Notes and References

1. Lishko PV, Maximyuk OP, Chatterjee SS, Nöldner M, Krishtal OA . The putative cognitive enhancer KA-672.HCl is an uncompetitive voltage-dependent NMDA receptor antagonist . NeuroReport . 9 . 18 . 4193–7 . December 1998 . 9926872 . 10.1097/00001756-199812210-00035 . 29960822 .
2. Winter JC, Helsley SE, Rabin RA . The discriminative stimulus effects of KA 672, a putative cognitive enhancer: evidence for a 5-HT1A component . Pharmacology, Biochemistry, and Behavior . 60 . 3 . 703–7 . July 1998 . 9678654 . 10.1016/S0091-3057(98)00043-4 . 6493994 .
3. Hoerr R, Noeldner M . Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment . CNS Drug Reviews . 8 . 2 . 143–58 . 2002 . 12177685 . 6741668 . 10.1111/j.1527-3458.2002.tb00220.x .
4. Knauber J, Müller WE . Anseculin improves passive avoidance learning of aged mice . Pharmacological Research . 47 . 3 . 225–33 . March 2003 . 12591018 . 10.1016/S1043-6618(02)00311-0 .
5. Sourgens H, Hoerr R, Biber A, Steinbrede H, Derendorf H . KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers . Journal of Clinical Pharmacology . 38 . 4 . 373–81 . April 1998 . 9590466 . 10.1002/j.1552-4604.1998.tb04438.x . 32558296 .